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had died. The use of nimorazole improved the loco-regional 
tumour control with an 18 months post-randomisation 
cumulative failure rate of 31% versus 54% in the control 
group, yielding a risk difference of 23% (CI 2%-45%; P= 0.03). 
The corresponding values for overall death was 39% versus 
68%; risk difference 28% (CI 4%-52%; P= 0.02).  
Conclusions: Although the trial was incomplete and suffered 
from small and incomplete number of patients, did the 
analysis indicate a loco-regional control and survival benefit 
in patients given the hypoxic modifier nimorazole in addition 
to accelerated fractionation for advanced HNSCC. 
However, the trial also revealed that conducting multicenter 
and multinational clinical studies combining drug and 
radiotherapy in developing countries, may suffer from 
uncontrolled and unsolvable problems. 
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Purpose/Objective: Patients with incurable locally advanced 
non-small cell lung cancer (NSCLC) (mainly Stage IIIB) usually 
receive palliative treatment with either radiotherapy (RT) 
alone (39 Gy in 13 fractions or 10-17 Gy in 1-2 fractions) or 
several cycles of doublet chemotherapy (CHT) regimens. In 
order to optimize treatment approach in this disease and 
improve access to RT in limited resource setting, 
International Atomic Energy Agency conducted a prospective 
randomised study (NCT00864331) comparing protracted RT 
course with CHT followed by one or two fractions of RT. 
Materials and Methods: Total of 65 patients from 7 
institutions aged ≥ 18 years, with histologically confirmed 
NSCLC, stage IIIA/IIIB, Karnofsky performance status (KPS) 60-
90, previously not treated for NCSLC were randomised, 31 to 
arm A and 34 to arm B. Exclusion criteria were RT field > 200 
cm2 and pregnancy. In arm A, RT consisted of 39 Gy in 13 
fractions. In arm B, 2 to 3 platinum-based CHT cycles were 
prescribed, and were followed by 10 Gy given in a single 
fraction or 16 Gy given in 2 fractions separated by one week. 
Further treatments depended on disease progression and 
patient condition and were left to the discretion of involved 
radiation oncologist. Primary outcome was overall survival.  
Results: Treatment groups were balanced with respect to 
various variables (Table 1). Treatment compliance was also 
given in Table 1.  
 
With follow-up through Feb 2014, 6/65 remained alive, 3 in 
each arm (all 6 being lost to follow-up at > 1 yr of 
observation). Median survival for all 65 patients was 0.66 yr 
(maximum 5.0 yr), while median survival was 0.59 and 0.68 
yr for the two arms, respectively (log-rank p=0.4 by study 
arm, and p=0.6 by Cox regression, stratified by country and 
sub-stage). One- to three-year survival rates for the two arms 
were 29%, 9% and 9% vs 41%, 12% and 6%, respectively) 
(Figure 1). 
  
There was no difference in any of the following endpoints (all 
values, p>0.5): any failure, occurring in 26 cases each in A 
and B; local failure, occurring in 18 cases each; regional 
failure, occurring in 6 and 8 cases in the two arms, 
respectively; contra-lateral thoracic disease, occurring in 3 
cases each; and distant failure, occurring in 13 and 14 cases 
in the two arms, respectively. Post-initial treatment, in arm 
A more courses of palliative RT were administered (17 
courses in 11 cases, vs. 4 in 4 cases in arm B), along with 
slightly more palliative CHT cycles (19 cycles in 7 cases, vs. 
11 in 2 cases in arm B).  
Conclusions: There were no differences in survival, relapse 
patterns and symptoms between the two arms. When 
compared to high-dose palliative RT, CHT followed by one or 
two fractions of RT produced similar results. It can be 
recommended as treatment approach, especially in limited 
resource setting, where access to RT remains inadequate.  
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Purpose/Objective: The irradiation of lymph node regions in 
the post-mastectomy setting has been a matter of 
uncertainty. EORTC trial tested the irradiation of the internal 
mammary chain (IMC) and medial supraclavicular nodal 
region (SNR) in node-positive medial/central tumours and 
detected a 1.6% benefit in survival and 3% benefit in DFS at 5 
years. The preliminary results of the MA.20 suggest that 
regional irradiation may reduce distant metastases. A meta-
analysis of randomized trials concluded that irradiation of the 
lymph node regions improves outcomes. 
Materials and Methods: The IAEA conducted a prospective 
randomized clinical trial to compare the local control, 
regional control, overall and disease-free survival of stage IIA 
– IIIA breast cancer patients randomly assigned to post-
mastectomy radiotherapy with or without irradiation of the 
SNR, and to compare the acute and late adverse events 
associated with radiotherapy in both study arms. 
Between July 2007 and December 2012, women with 
mastectomy (minimum 6 removed nodes but not more than 9 
positive) and negative margins, who had received adjuvant 
chemotherapy, were centrally randomized to receive, as 
adjuvant, 40 Gy in 15 fractions to: the chest wall concurrent 
with 40 Gy in 15 fractions to the SNR; or chest wall (CW) 
irradiation alone. There was no attempt to irradiate the IMC. 
Recurrences were classified relative to the irradiation 
volumes as 'local' (in the CW fields), 'regional' (in the SNR 
location), and 'others'. 
Results: There were 469 women randomized, 237 to CW+SNR 
irradiation and 232 to CW only. The mean follow-up was 3.4 
years from mastectomy. By order of SNR and CW there no 
statistically significant differences for: 7 vs. 1 local failure; 8 
vs. 3 regional failures; and 37 vs. 33 distant failures. These 
events affected 75 patients (crude 16%). With 60 deaths 
(crude 12.8%) the overall survival by Kaplan-Meier was 84% at 
5-yr from mastectomy. This was not statistically different 
between trial arms (82% CW+SNR vs. 87% CW, p=0.17 by 
stratified analysis, further adjusted for stage and negative 
receptor status).  
In 283 patients with 1-3 positive axillary nodes, and with a 
3.4 years median follow-up, the overall survival was 
equivalent, and very similar results were also observed for 
the 57 cases with only upper-inner quadrant primaries, of 
whom 52 were node-positive in the axilla. There was no 
difference in the experience of toxicities including arm 
lymphedema. 
Conclusions: There was no difference in local, regional or 
distant failures or in toxicities across study arms. 
Hypofractionation was adopted by participating centres, thus 
sparing resources. Long term follow-up is needed for a 
definitive conclusion on the postoperative value of SNR 
irradiation in addition to effective systemic therapy. 
Although well tolerated, SNR irradiation did not show a 
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Purpose/Objective: Evidence is limited for locally advanced 
non-metastatic rectal cancer as to whether it is best 
managed with neo-adjuvant chemo-radiation (50 Gy/25 
fractions, A). Short-course radiotherapy (RT) (25 Gy/5 
fractions) would spare RT resources and it could be followed 
by two cycles of chemotherapy prior to surgery (B). This 
prospective, international, multi-center randomized trial of 
the IAEA compares A with B, surgery equally intended four 
months post-randomization. 
Materials and Methods: A total of 142 patients were accrued 
Apr 2011 to Jan 2014 (78 Mumbai, 15 Croatia, 15 Cape Town, 
12 Cuba, 11 Colombia, 7 Indonesia, 3 Coimbatore and 1 
Pretoria). A further 5 recently randomized cases are not yet 
evaluable. Radiation was 3-D planned, and for T4 cases 
included involved organs and anterior pelvic nodes. Primary 
outcomes were surgical resection and pathological margin 
status. At five months, patients were to receive a course of 
chemotherapy. Scheduled follow-up was every 3 months if 
with disease, or every 6 months if no evidence of disease. 
Relative safety of the two treatment regimens was 
determined from grades of adverse events (AE, CTCv4), 
stoma-related events and lab. tests. 
Results: Long-course (A) and short-course (B) arms had 71 
patients each with no statistical differences in patient and 
disease variables at baseline. Mean age was 50.7 yr and 93 
were male. Pathology on initial biopsy was 20 G1, 97 G2, and 
25 G3. Tumor location was 100 lower, 34 mid, and 8 upper 
rectums. Mean tumor length was 6.8 cm (range 2-20 cm) with 
a mean CEA of 25.9. Stage on initial imaging was 60 T4, 81 T3 
and 1 T2, plus 44 N2, 71 N1 and 37 N0. The CRM was deemed 
at-risk in 130 (82/82 non-T4 and 48/60 T4 cases). Fixity was 
in 52%, with 22% tethered and 26% mobile. Follow-up through 
Nov 2014, to a maximum 3.5 yr, gave a mean observation 
time of 1.54 yr for all 100 cases still alive. With 17 A and 25 B 
cases deceased, overall survival by Kaplan-Meier at 2.5 yr 
was 63% for A (95CI 47-76%) and 55% for B (95CI 39-68%); p = 
0.13 by Cox regression stratified by participating center and 
if T4. During neo-adjuvant treatment, CEA decline and down-
